The MEF2C Foundation UK has announced a major milestone in its ongoing fight against MEF2C Haploinsufficiency Syndrome (MHS), a rare genetic disorder affecting fewer than 500 people worldwide, with just 52 of those in the UK. During Rare Disease Day 2026, the charity's "Pathways to Hope" fundraising campaign successfully raised over half a million pounds, surpassing its £400,000 target. The campaign was recognised on the official Rare Disease Day 2026 heroes page.
A bridge to human clinical trials
The funds raised through Pathways to Hope are earmarked for two specific, mandatory milestones: a natural history study to map how MHS progresses across patients over time, and a toxicology study to establish safety data, both required before regulatory approval for human trials can be pursued. Without these studies, a treatment cannot move from the lab to the clinic. The foundation has now cleared the funding hurdle for both.
A Global Consortium Approach
The MEF2C Foundation UK operates as part of a global consortium — a network of sister organisations spanning the US MEF2C Foundation, Rare Bird Foundation, MEF2C Foundation Australia, MEF2C Foundation Germany (Mef2c Hilfsorganisation), and leading research institutions including Weill Cornell Medical Center and the Medical University of South Carolina (MUSC).
The consortium shares a concrete, time-bound target: be ready for human clinical trials within three years. That deadline has milestones behind it, not just optimism. The Pathways to Hope funds directly support the next two steps on that timeline.
The Science Behind the Fundraising
Two landmark papers published in Nature Immunology and Cell Immunity in 2025 identified the MEF2C-p21-CDK2-RB-NFκB pathway — the mechanism by which MEF2C deficiency causes microglial overactivation and neuroinflammation. This discovery transformed MHS from a poorly understood developmental syndrome into a condition with a clear, druggable therapeutic target.
The finding established that CDK2 inhibitors — a class of drugs already being tested for cancer — may be repurposable for the neuroinflammatory aspects of MHS. This validation has been a major driver of the consortium's strategy, which now spans multiple therapeutic approaches:
- CDK2 inhibitor repurposing (currently in Phase 1a/b trials for solid tumours, with brain-penetrant compounds like AL-605 advancing)
- Gene therapy (AAV-based approach led by UT Southwestern, funded by the MEF2C Family Foundation)
- RNA therapeutics (MUSC team, with 8 candidate compounds showing 40–60% efficacy in early experiments)
- Natural history and regulatory preparation (the work Pathways to Hope now funds)
The Path Forward
What makes this milestone significant is the specificity of the ask. The consortium isn't raising money for general awareness or vague "research." Every pound raised through Pathways to Hope goes toward:
- The natural history study: establishing baseline disease progression data across the global MHS population
- The toxicology study: proving treatment safety to regulatory bodies
- Consortium coordination: keeping the global effort unified, funded, and on schedule
With both milestones now funded, the consortium has cleared two of the most significant administrative and scientific hurdles on the road to human trials. The next checkpoint is regulatory submission, with the three-year timeline remaining on track.
For families affected by MHS — the roughly 500 worldwide, the 52 in the UK, and the thousands more waiting for answers — this is the kind of progress that turns "someday" into "this decade."